Liva Healthcare are digitizing personal healthcare. The company's digital health platform provides users with personalized coaching and tailored lifestyle plans. Currently the company offers digital programs for weight management and diabetes prevention. Visit website.

Locate Bio is working to solve some of the most complex degenerative and infectious diseases that affect the muscular skeletal system. Locate utilises Programmed Drug Release to re-align the bioavailability of existing drugs with the underlying biological need. This bio-optimisation step has demonstrated break through improvements in performance in preclinical testing. Locate Bio is reshaping rhBMP-2 perspectives with its unique, delayed presentation of rhBMP-2. It’s lead product, LDGraft is being evaluated in a human clinical study. In a large animal model, the product has demonstrated equivalent efficacy to the gold standard, but more importantly, an excellent safety profile, with none of the adverse events reported by other studies. Visit website.

Pi is a multimodal software platform for cancer imaging and diagnostics. It is CE certified and deployed across Europe and the UK to support the analysis of MRI scans for prostate cancer, the most common cancer in men. Visit website.

Lupin Dental has created an end-to-end solution to deliver beautiful and clinically excellent smiles to patients using planning software and a supervised automated robotic treatment platform. Lupin Dental’s robotic solution enables every dentist to achieve best-in-class minimally invasive tooth preparation for porcelain laminate veneers repeatably and accurately, thereby restoring the patients’ teeth following best in class aesthetic and clinical practice. Visit website.

May Health is developing a minimally invasive treatment for polycystic ovary syndrome (PCOS), a leading cause of female infertility due to ovulatory dysfunction. Current treatment options—including drug therapy, surgical ovarian drilling, and IVF—carry risks such as multiple pregnancies, invasiveness, and high costs. May Health’s approach aims to replicate the effectiveness of ovarian drilling while reducing procedural risk and invasiveness. The goal is to enable more natural conception pathways for women with PCOS. Visit website.

Develops and offers a diverse range of products to control bleeding. The company's lead product, LifeGel, is a resorbable surgical hemostat intended to manage a range of bleeding severities across different tissue types while offering critical safety and cost advantages. Visit website.

Medyria has developed the PyCath, a microcatheter for full Coronary physiology targeted to therapy optimization. The PyCath awaits FDA clearance and will be launched in US in 2026. Visit website.

Microsure’s MUSA robot enables microsurgeons to perform sub-millimeter anastomosis for patients who - for example - had to undergo breast amputation or suffer from lymphedema. Visit website.

Nano4Imaging has developed an magnetic resonance (MR) compatible guidewire to transfer select cardiovascular procedures from the cathlab to the MRI suite. Initially focused on developing their solutions for congenital heart diseases, the company plans to expand their technology into interventional procedures, such as angioplasty. Visit website.

NeoCor develops the CoApt Valve®, a transcatheter device designed to treat severe mitral and tricuspid valve disease through a minimally invasive approach. The CoApt Valve features a self-expanding nitinol frame and an electrospun polymeric valve, aiming to reduce or eliminate regurgitant jets without the need for open-heart surgery. The device is delivered via a catheter inserted through the transfemoral vein, preserving the native valve structure. CoApt Valve is advancing its technology through preclinical studies in both canine and human models, with plans to initiate veterinary clinical trials.​ Visit website.

NeoPredics develops advanced predictive clinical decision support solutions using machine learning and AI algorithms to assess maternal and neonatal health risks. Their primary focus is on early detection of conditions such as preeclampsia and jaundice, providing data-driven insights to improve outcomes in high-risk pregnancies and newborn care. Visit website.

Neuroelectrics unlocks the power of computational neuroscience to treat brain disorders. Pioneering non-invasive tech for personalized neuromodulation, aiming to restore brain health & improve lives. Visit website.

New Phase developed Nanotechnology which brings new hope for people facing stage IV cancer, where current treatments can be limited, with low response rate, and severe side effects.Our approach focuses on prolonging patients’ lives while preserving the quality that makes life meaningful. The technology combines nanoparticles containing multicore superparamagnetic iron oxide coated by a biocompatible polymer which are delivered to the cancer tissues and are heated to 50°C using an Electromagnetic Induction Systems (EIS) which generates an Alternating Magnetic Field (AMF) and applies electromagnetic hyperthermia, causing destruction to the cancer cells since they are more sensitive to heat, leaving healthy cells unharmed. Visit website.

Newronika's AlphaDBS is a closed-loop deep brain neuromodulation system. The device interprets the bioelectrical neuronal activity (local field potentials, LFPs) in the brain areas where stimulation is delivered and accordingly adapts moment-by-moment the stimulation to follow patient’s clinical condition. The technology is being developed as a treatment for Parkinson's disease. Visit website.

NIMBLE is developing a first-in-class, non-invasive, non-ionizing system to monitor coronary stent health using microwave-based technology. Designed to detect occlusion, fracture, or migration, the NIMBLE System provides cardiologists with objective data on stent status—without relying on invasive angiograms. With over 4 million stents implanted annually and a 30% failure rate within two years, NIMBLE addresses an $8B market with the goal of improving outcomes and saving lives. Visit website.

Nitinotes develops the EndoZip™, the first fully automated endoscopic suturing system for Endoscopic Sleeve Gastroplasty (ESG), a minimally invasive weight-loss procedure. Designed for efficiency, EndoZip enables a single-operator ESG procedure with automated, standardized suturing, reducing variability, procedure time, and training requirements. The system facilitates outpatient treatment with low-risk and predictable outcomes, addressing the growing need for effective, non-surgical obesity interventions. Visit website.

Njord is a medtech spin-off from Sahlgrenska University Hospital with a mission to solve unmet needs in radiology and patient handling. The first product launched is a novel patient transfer device (co-bot solution) Atle® 180 enabling improved efficiency and quality of care for acute care departments. The solution is already in use by +30 hospitals in Northern Europe. Visit website. 

Noah Labs Vox eliminates the no. 1 cause of hospital admissions - congestive heart failure - 2 weeks before hospitalization by analyzing voice changes caused by fluid build-up in the lungs and vocal tract. Trained on the world's largest heart failure voice data set, the patented technology is being piloted at Mayo Clinic, UCSF and Charité Berlin.  Visit website.

Novuson’s patented DTU technology will represent the first substantive innovation in over 25 years for targeting vessel sealing / dividing, and hemostasis (bleeding control) in surgical and trauma applications. Visit website.

Noze is enabling early disease diagnostics through digital odor perception. The company is developing an advanced digital nose that is capable of accurately detecting and identifying odors in real-world settings. The company’s mission is to enable real-time disease detection at the point-of-care through the identification of breath-based odor biomarkers.  Visit website.

Osteal Therapeutics is a musculoskeletal therapeutics company developing solutions for the treatment of orthopedic infections. The company's lead product, VT-X7, is a drug-device combination that utilizes high concentrations of vancomycin and tobramycin, in conjunction with a drug delivery system, to irrigate infected joint spaces as a result of periprosthetic joint infection in joint replacement patients.  Visit website.

Panda Surgical, a University College London spinout, is introducing the world's smallest robotics and AI platform for minimally invasive neurosurgery, offering surgeons enhanced dexterity and decision-support to make these operations safer, more effective, and more widely adopted. Visit website.

Pixee Medical develops augmented reality solutions for implant placement that offer orthopedic surgeons cutting-edge and clinically proven tools for precise and efficient surgery. Its first generation Kneeᐩ technology has already been used in over 10,000 procedures in more than 20 countries, demonstrating its positive impact on surgical practices worldwide. Visit website.

Planatome is a patented technology platform, adapted from semiconductor manufacturing and licensed to industry leaders to create the world’s most advanced surgical cutting instruments – think semiconductor meets medical. Visit website.

Plexāā is a UK-based MedTech company developing innovative solutions to improve surgical outcomes. Its flagship device, BLOOM⁴³, is a fully wearable system designed to precondition the skin before breast surgery by gently warming the area to stimulate the release of Heat Shock Proteins, which improve blood flow and support healing. Clinical trials have shown that this approach can reduce wound healing complications such as infection and skin necrosis. Plexāā is also investigating applications of this technology in other surgical areas including obstetrics, orthopedics, and vascular surgery. Visit website.

Polarean’s Xenon MRI platform, now commercially available in the United States for patients six years and older, uses the first and only FDA-approved inhaled contrast agent (XENOVIEW®) to provide functional lung imaging that visualizes regional ventilation and gas exchange without radiation. The platform integrates with MRI systems from GE HealthCare, Philips, and Siemens Healthineers, supporting earlier diagnosis, treatment planning, and monitoring of lung diseases. It also serves as a sensitive tool for drug development, enabling quantitative assessment of therapeutic response. Visit website.

Precision Cardiovascular is focused on enhancing the outcomes and quality of life for patients with heart failure. The company is developing a miniature sensor that is placed in the pulmonary artery to continuously collect and analyze data to improve the remote management of cardiovascular diseases. Visit website.

EASEE is Precisis' neurostimulation device that can act in two modes - excitatory and inhibitory. The duality of the device allows its to be used for the treatment of many cerebral diseases, including epilepsy, depression, and cognitive disfunctions caused by stroke. Precisis is currently developing a close-loop system for their EASEE technology, which will allow the device to record brain activity and respond with targeted stimulation. Visit website.

Pulnovo Medical is developing radiofrequency (RF) solutions for the treatment of pulmonary hypertension. PADN is a multipolar synchronous pulmonary artery RF ablation catheter that is intended to treat pulmonary hypertension by ablating the sympathetic nerve at the target site. The device is capable of point-to-point ablation of pulmonary sympathetic nerves. Visit website.

Rekovar develops wearable biosensor technology aimed at improving the management of Neonatal Abstinence Syndrome (NAS). Its flagship product, NeoMonki, is an investigational neonatal monitoring kit designed to provide real-time, objective data on infants' physiological and behavioral states. The system includes a wristband sensor, imaging camera, tablet application, and a provider portal, enabling healthcare professionals to deliver personalized care and intervention. Visit website.

Relief Srl is an innovative Italian MedTech company developing a first-in-class device for the treatment of stress urinary incontinence (SUI). Visit website.

ReVision Implant is developing the world's first prosthesis that restores useful vision to blind people. We are using implants with thousands of microelectrodes and advanced stimulation algorithms to directly transmit video to the visual cortex of the brain. Visit website.

SamanTree Medical's Histolog Scanner is a digital microscopy scanner for high-resolution imaging of the surface of fresh tissue. The device utilizes novel, ultra-fast confocal microscopy technology to enable rapid histological assessment in the operating room or pathology laboratory.  Visit website.

ScienceForBrain is developing a medical technology designed to protect brain function during cardiac bypass surgeries and neuro-intensive care. Built on over 30 years of research and multiple patents, the system enables heart-lung machines to generate regular rectangular blood flow pulsations, allowing real-time assessment of cerebral autoregulation. This capability helps clinicians maintain optimal brain perfusion tailored to each patient, with the aim of reducing postoperative complications such as delirium and cognitive decline. Visit website.

Seerlinq is the first certified medical device to offer non-invasive, cost-effective monitoring of cardiac filling pressure from home. The telemonitoring service can detect heart failure decompensation up to 30 days in advance, helping to prevent hospitalizations and deaths using just a simple oximeter or smartwatch. Seerlinq has been shown to reduce hospitalizations by up to 80%, making it one of the most effective non-invasive interventions. Already reimbursed and in clinical use across Slovakia, Seerlinq is now entering the German market and partnering with a leading smartwatch brand to scale heart failure diagnostics and monitoring globally. Visit website.

Transforming the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient. Visit website.

Sequana Medical NV develops technologies to treat diuretic-resistant fluid overload in liver disease, heart failure, and cancer. Its alfapump device, approved by the FDA as a breakthrough and PMA-approved, is a fully implantable pump that automatically moves excess fluid to the bladder for natural excretion, targeting recurrent ascites from liver cirrhosis. Sequana Medical is also advancing DSR, a phase IIa drug program aimed at treating diuretic resistance and cardiorenal syndrome in heart failure. Both technologies address large and growing markets driven by increasing disease prevalence. Visit website.

Serox is developing low-cost, non-invasive IVDs for high-incidence diseases at the point of care. By combining Raman Spectroscopy, Surface Enhanced Raman Spectroscopy (SERS), and machine learning, Serox enables the detection of cancers and infections in urine without the need for invasive procedures like blood draws or cystoscopy. The company is initially focused on bladder, prostate, and kidney cancers, with plans to expand into women’s cancers and urinary tract infection diagnostics. Serox’s technology aims to streamline screening and reduce unnecessary interventions through fast, accurate, and personalized urine-based testing. Visit website.

Solenic Medical is developing a non-invasive medical device that utilizes alternating magnetic fields to eradicate biofilms that form on implants. The company's platform uses external magnetic coils to destroy infective biofilms on the surface of knee and hip replacement implants, as well as plates and rods for trauma related procedures. Solenic's solution is being developed to replace the expensive and risky two-step revision surgery, which is the current standard of care for chronic infections on medical implants. Visit website.

Sonion Health is developing a biosensing digital health platform for cuffless blood pressure monitoring, addressing hypertension as a major risk factor for cardiovascular mortality. The technology has been developed over several years by Sonion engineers, known for their expertise in balanced armature receivers, premium microphones, and electromechanical devices. This platform aims to enhance hypertension management through continuous, non-invasive monitoring.

The first osseointegrative biomimetic knee cartilage implant. Visit website.

Spinally is developing an intrathecal spinal cord stimulation and recording system that significantly improves on existing neuromodulation solutions. Unlike conventional products, Spinally’s technology offers superior spatial precision and deeper stimulation capabilities while consuming less power. It also enables high-fidelity neuronal signal recording, supporting closed-loop approach. The device is designed for rapid deployment using a micro-needle insertion method, which simplifies the surgical process and minimizes patient recovery time. Our initial focus is chronic pain. However, the system's design and performance open opportunities across a broader range of therapeutic applications: Parkinson’s disease, neurorehabilitation, and spine-computer interface, creating a path toward treating complex neurological conditions with greater specificity and adaptability. Visit website.

STENTiT is developing a novel class of regenerative implants, solely composed from resorbable fibers. The balloon expandable implant provides instant structural support to keep the artery open, while allowing circulating blood cells to infiltrate into the porous mesh. This triggers a natural healing response by which immune cells gradually replace the mesh with new vascular tissue as the implant safely dissolves over time. Hereby, the RFS fully reconstructs the artery from the inside out. In addition, the fibrillated design allows to be scaled beyond 100 mm to serve the majority patient population. Visit website.

Tensive is a biomedical startup, which develops innovative scaffolds aiming to offer a natural breast reconstruction or augmentation. Tensive’s long-term mission is to restore a natural breast to patients, who experienced reconstructive surgery after mastectomy or lumpectomy, to improve their quality of life and avoiding recurrent and expensive surgical operations. Visit website.

TYBR Health is developing a natural hydrogel to prevent adhesions (internal scarring) that can occur following minimally invasive surgery. The technology is intended to reduce post-operative complications which can cause patients pain and require rehabilitation following tendon and joint surgeries.  Visit website.

UNEEG Medical A/S develops cognitive technologies for continuous brain activity monitoring (EEG) to support medical and diagnostic applications. The company specializes in ultra long-term subcutaneous EEG monitoring with its CE-marked 24/7 EEG™ SubQ solution, designed to detect electrographic seizures in daily life. UNEEG’s technology provides objective insights into seizure burden for epilepsy management and aims to alert diabetics of severe hypoglycemia. The company employs approximately 100 people and has recently begun an international market launch. Visit website.

Vena Vitals is an early stage med-tech company focused on non-invasive continuous blood pressure monitoring. The company's proprietary technology is a soft flexible sensor that conforms to the skin for direct pressure measurement at theradial artery. The company's technology is intended to replace unnecessarily invasive arterial line measurements as well as non-continuous cuff-based methods in both the hospital and at home. Visit website.

Our novel pVAD technology is the most powerful and smallest pVAD technology that we know, able to provide over 7L/min at physiological pressures and provide total left ventricular support for cardiogenic shock and other critically ill patients. Total support has been shown to reduce infarct size for heart attack patients, and the recent DanGer shock trial has validated the use of pVAD technology in cardiogenic shock patients. The technology is based on 7 granted patents and no catheter or sheath larger than 9Fr is used in the percutaneous, Cath lab, implant procedure.  Visit website.

VirtaMed develops mixed-reality surgical simulators designed to enhance medical education and improve patient outcomes. Its platforms integrate real surgical instruments with haptic feedback and photorealistic graphics to provide immersive training experiences across specialties such as orthopedics, obstetrics and gynecology, urology, and general surgery. VirtaMed also offers customizable training solutions for medical device companies and educational institutions, supported by its cloud-based platform, VirtaMed Connect, for performance tracking and curriculum development. The company is headquartered in Zurich, Switzerland, with additional locations in the United States and China. Visit website.

Wellumio is a venture-backed company specializing in portable MRI solutions for acute neuroimaging applications. The company’s core enabling technology is a novel pulse-gradient free nuclear magnetic resonance sensor platform with an initial focus on acute stroke triage and diagnosis. Visit website.

WISE S.p.A. is developing next-generation electrodes for neuromonitoring, neuromodulation, and brain-machine interfaces using its proprietary Supersonic Technology. The company’s portfolio includes the FDA-cleared WISE Cortical Strip for intraoperative monitoring and the Heron® lead, the first percutaneous directional lead for spinal cord stimulation. WISE’s thin, flexible electrodes offer superior neural tissue conformity and minimal invasiveness. These innovations aim to disrupt the $3B SCS market and advance care across multiple neuro applications. Visit website.

Yaqrit is developing an extracorporeal liver support system aimed at critically ill patients with multiple organ failures. The system removes blood toxins and replaces dysfunctional albumin to support recovery from acute-on-chronic liver failure (ACLF). Clinical data indicates a 67% improvement in patient outcomes over 10 days. Visit website.